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In addition to its canonical role in nuclear transcription, signal
transducer and activator of transcription 3 (STAT3) is emerging
as an important regulator of mitochondrial function. Here, we
demonstrate that a novel inhibitor that binds with high affinity to
the STAT3 SH2 domain triggers a complex cascade of events
initiated by interference with mitochondrial STAT3 (mSTAT3). The
mSTAT3–drug interaction leads to mitochondrial dysfunction, ac-
cumulation of proteotoxic STAT3 aggregates, and cell death. The
cytotoxic effects depend directly on the drug’s ability to inter-
fere with mSTAT3 and mitochondrial function, as demonstrated
by site-directed mutagenesis and use of STAT3 knockout and
mitochondria-depleted cells. Importantly, the lethal consequences
of mSTAT3 inhibition are enhanced by glucose starvation and by
increased reliance of cancer cells and tumor-initiating cells on mi-
tochondria, resulting in potent activity in cell cultures and tumor
xenografts in mice. These findings can be exploited for eliciting
synthetic lethality in metabolically stressed cancer cells using high-
affinity STAT3 inhibitors. Thus, this study provides insights on the
role of mSTAT3 in cancer cells and a conceptual framework for
developing more effective cancer therapies.
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Signal transducer and activator of transcription 3 (STAT3) is akey element in multiple signaling pathways and is aberrantly
activated in many human cancers (1, 2). STAT3 promotes cell
proliferation, survival, angiogenesis, and immune-evasion (1–3).
Phosphorylation at Tyr705 (pTyr705), catalyzed by Janus kinases
(JAK) and other tyrosine kinases, induces STAT3 dimerization
through the interaction of the SH2 domain (SH2D), nuclear
accumulation, and target gene transcription (1, 3, 4). Emerging
evidence indicates that STAT3 also localizes to mitochondria
and controls mitochondrial functions (2, 5–7). Mitochondrial
localized STAT3 (mSTAT3) is critical for survival of RAS-
transformed mouse embryo fibroblasts (MEF) under glucose-
starvation, reflecting a specific dependency of cancer cells on
mitochondria in certain conditions (6). Interestingly, mSTAT3 is
prevalently phosphorylated at Ser727 (pSer727), which enhances
its mitochondrial functions (5, 6). Furthermore, constitutive
pSer727 is found in many human cancers and is apparently suf-
ficient to drive tumorigenesis in various model systems (8–10).
STAT3 is an attractive cancer therapeutic target because of
its central role in multiple oncogenic processes and great effort
has been devoted in recent years to discover STAT3 inhibitors
(STAT3i) (11, 12). To date, small-molecule STAT3i have shown
relevant activity in preclinical models and few of them are cur-
rently investigated in clinical trials (11, 13–17). However, an
important gap persists in our knowledge of the biological
mechanisms of antitumor activity, the critical cellular processes
affected, and the factors determining sensitivity of cancer cells to
STAT3i, hindering further clinical development of these highly
promising anticancer drugs. Indeed, great attention has been
devoted to the effects of direct and indirect STAT3i on nuclear
and transcriptional functions of STAT3, whereas much less is
known about the consequences of STAT3 inhibition on mito-
chondrial activity (11, 12). The emerging role of mitochondria as
central organelles in metabolic adaptation, drug resistance, and
stemness in human cancers makes this issue timely and relevant
(18–21).
In this study, we investigated how a novel small-molecule
compound, OPB-51602, which is currently in clinical trials (16,
17), interferes with the STAT3 functions in cancer cells. We
show that OPB-51602 binds with high affinity to the SH2D and
inhibits very effectively STAT3 phosphorylation and cancer
cell proliferation. Intriguingly, we found that, upon binding to
STAT3, OPB-51602 triggers a complex cascade of events that
includes disruption of mitochondrial function and protein ho-
meostasis, culminating in cell death. These events were initiated
by binding to the SH2D and interference with mSTAT3. Notably,
the lethal consequences of OPB-51602 were greatly enhanced by
glucose starvation and reliance on mitochondrial function. This
created a condition of synthetic lethality, leading to high vulnera-
bility of cancer cells and tumor-initiating stem-like cells to STAT3i
and potent antitumor effect in tumor xenografts. Importantly, this
concept of mitochondrial targeting by small-molecule STAT3i
could be exploited to design novel therapeutic strategies and drug
combinations for cancer treatment.
Significance
The transcription factor STAT3 is involved in multiple onco-
genic signaling pathways and is an attractive therapeutic tar-
get. This study shows that a potent inhibitor of STAT3
interferes with mitochondrial activity and protein homeostasis,
leading to a synthetic lethality effect in glucose-depleted can-
cer cells. These findings provide a rationale for novel strategies
based on the use of STAT3 inhibitors for cancer treatment.
Author contributions: D.G., G.M.C., and C.V.C. designed research; D.G., L.B., E.L., J.M.,
G.C., S. Pandit, R.D., L.P., and S. Pricl performed research; D.E.L. and S. Pricl contributed
new reagents/analytic tools; D.G., L.B., E.L., J.M., G.C., S. Pandit, R.D., L.P., D.E.L., S. Pricl,
G.M.C., and C.V.C. analyzed data; and C.V.C. wrote the paper.
Conflict of interest statement: This work was partially funded by Otsuka Pharmaceuticals
(Japan), which provided and owns patents on two compounds used in the study, OPB-
51602 and OPB-31121.
This article is a PNAS Direct Submission.
1D.G., L.B., and E.L. contributed equally to this work.
2To whom correspondence should be addressed. Email: carlo.catapano@ior.iosi.ch.
This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.
1073/pnas.1615730114/-/DCSupplemental.















OPB-51602 Inhibits STAT3 by Binding to the SH2D. To gain insights in
the biological activity of OPB-51602, we tested its effects on cell
proliferation and STAT3 signaling in human cancer cells. OPB-
51602 inhibited cell growth (Fig. 1A) and clonogenic capability
(Fig. 1B) of DU145 and H358 cells. The response to OPB-
51602 in cell growth assay was greatly affected by the culture
conditions, with increased sensitivity when cells were plated at
higher density (Fig. 1A). Under similar high-density culture
conditions, inhibition of pTyr705 and pSer727 was seen at
nanomolar concentrations and, within few hours of treatment
(≥90% at 10 nM at 4 h), in DU145 and H358 cells with consti-
tutive activation of pTyr705 and in LNCaP cells with inducible
pTyr705 in the presence of IL-6 (Fig. 1C and Fig. S1A). We
reasoned that the increased response at higher cell density could
be because of rapid depletion of nutrients from the cell culture
medium influencing the metabolic state of the cells. Consistently,
when we replaced the high-density culture medium—defined as
conditioned medium (CM)—with fresh medium (FM), the ef-
fects of the treatment on STAT3 phosphorylation was dramati-
cally reduced (Fig. S1B). This phenomenon was not unique to
OPB-51602 and the response to other STAT3i (OPB-31121 and
STA-21) was equally decreased in the presence of FM (Fig. S1C).
Conversely, we observed that the inhibition of pTyr705 by the JAK
inhibitor NVP-BSK805 was higher in FM than CM (Fig. S1D).
To prove that OPB-51602 binds to STAT3, we used compu-
tational modeling and binding assays by isothermal titration
calorimetry (ITC). Computational docking and molecular dy-
namics simulation identified a potential binding site for OPB-
51602 in the STAT3 SH2D (Fig. 1D) partially overlapping the
binding site of OPB-31121 (22). Energy decomposition analysis
was used to determine the contributions of individual amino
Fig. 1. Binding and inhibition of STAT3 signaling by OPB-51602. (A) Proliferation of DU145 and H358 cells incubated for 72 h with OPB-51602 at high (filled
symbols) and low (open symbols) cell density. (B) Colony-forming ability of DU145 and H358 cells treated with OPB-51602. *P < 0.01. (C) pTyr705, pSer727, and
tSTAT3 in DU145 cells treated with OPB-51602 for 16 h (Upper) or 10 nM for the indicated time (Lower) in CM. (D) Model of the full-length STAT3 (firebrick
ribbon) in complex with OPB-51602 (blue). (E) Estimated binding free energy of WT, S636A, V637A, and E638A mutants of the STAT3 SH2D with OPB-51602.
Lower section shows molecular simulation of OPB-51602 bound to WT (green) or E638A (blue) SH2D. (F) ITC analysis of OPB-51602 binding to WT STAT3 SH2D.
(G) ITC analysis of OPB-51602 binding to STAT3 SH2D mutants (E638A, V637A, and S636A).
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acids in the binding pocket (Fig. S1E). In silico mutagenesis of
S636, V637, and E638 reduced substantially binding with esti-
mated IC50 values increasing from about 7 nM to >1,000 nM
(Fig. 1E). The in silico predictions were confirmed by ITC with
recombinant GST-tagged STAT3 SH2D, which showed that
OPB-51602 binds with Kd of 5 nM (Fig. 1F). Furthermore,
confirming the binding-site predictions, OPB-51602 did not bind
the S636A, V637A, and E638A SH2D mutants (Fig. 1G).
OPB-51602 Interferes with mSTAT3 and Mitochondrial Function. We
took advantage of the high-affinity binding of OPB-51602 to ex-
amine the effects of STAT3 inhibition on mitochondrial func-
tion in cancer cells. Mitochondrial membrane potential (MMP)
was drastically affected in cells treated with OPB-51602 in CM
(Fig. 2A and Fig. S2A). Conversely, MMP decreased only slightly
after treatment in FM (Fig. S2B). ATP production also de-
creased significantly after treatment in CM (Fig. S2C). Lactate
level (Fig. S2D), ATP production (Fig. S2E), and glucose uptake
(Fig. S2F) were not or minimally affected by the treatment in
complete FM, excluding a direct influence of the drug on glucose
metabolism. Furthermore, basal mitochondrial oxygen con-
sumption rate (OCR), along with respiratory capacity and mi-
tochondrial ATP production, were almost completely suppressed
after a 2-h incubation with OPB-51602 (Fig. 2B and Fig. S2G).
Interestingly, addition of OPB-51602 during the assay pro-
gressively inhibited mitochondrial activity compared with control
cells, suggesting that the drug acted rapidly to block mitochondrial
function (Fig. S2H). Using confocal microscopy, we monitored the
morphology of mitochondria in control and OPB-51602–treated
cells. Mitochondria were elongated and hyperfused in control
cells placed in nutrient-depleted CM and glucose-free medium
(Fig. 2C, Upper). This finding was consistent with dynamic ad-
aptation to nutrient starvation, whereby elongated mitochondria
ensure higher bio-energetic efficiency. Notably, in these condi-
tions OPB-51602 induced drastic changes in mitochondria that
appeared more fragmented, indicating an imbalance between
fission and fusion events, consistent with impaired mitochondrial
activity (Fig. 2C, Lower). These changes in mitochondrial function
Fig. 2. OPB-51602 impairs mitochondrial function. (A) MMP (JC1 staining) in DU145 cells treated with OPB-51602 and OPB-31121 for 2 h in CM. (B) Mito-
chondrial OCR in control and OPB-51602–treated (100 nM for 2 h) DU145 cells. (C) Mitochondrial shape in DU145 cells treated with OPB-51602 (100 nM) in CM
(16 h) or glucose-depleted medium (4 h) and stained with MitoTracker Orange (red) and DAPI (blue). (D) MMP (DIOC6 staining) in isolated mitochondria from
DU145 cells treated with OPB-51602 (50 μM) or Valinomycin (100 μM) for 3 h. (E) MMP (DIOC6 staining) in isolated mitochondria from WT and STAT3−/− MEF
treated with OPB-51602 for 3 h. (F) Cell viability [sulforhodamine B (SRB) assay] in DU145 and DU145 ρ° cells treated with OPB-51602. *P < 0.01.














and dynamics occurred rapidly, suggesting a direct effect on a key
mitochondrial target, and were favored by nutrient or glucose
depletion, reminiscent of the effect of STAT3 ablation in glucose-
starved cancer cells (6).
OPB-51602 binds tightly to STAT3 and the effect on mito-
chondria could be because of direct interference with mSTAT3
independent of the drug’s effect on nuclear STAT3. To test this
hypothesis, we treated with OPB-51602 mitochondria isolated
from DU145 cells. OPB-51602 reduced the MMP in line with
a direct impact on mSTAT3 (Fig. 2D). To further link this effect
to mSTAT3, we treated mitochondria isolated from WT and
STAT3−/− MEF. OPB-51602 affected mitochondria from WT
cells but was completely ineffective on mitochondria from STAT3-
depleted cells (Fig. 2E). Thus, mSTAT3 is a key target of OPB-
51602 in mitochondria and is essential for inducing mitochondrial
dysfunction. To establish whether interference with mSTAT3 was
also relevant for the drug’s cytotoxicity, we generated DU145 ρ°
cells depleted of functional mitochondria (Fig. S2I). The ρ° cells
were maintained in medium supplemented with uridine and py-
ruvate, which are essential for survival in the absence of mito-
chondria (23). Notably, mitochondria-depleted DU145 ρ° cells
were less affected by OPB-51602 (Fig. 2F). Thus, the drug’s cy-
totoxic effects depend on the ability to interfere with mSTAT3 and
inhibit mitochondrial function.
STAT3 Forms Proteotoxic Aggregates in the Presence of OPB-51602.
The induction of mitochondrial dysfunction and the dependency
on the cell metabolic state suggested that cancer cells in condi-
tions of increased reliance on mitochondria activity might be
more sensitive to the cytotoxic effects of OPB-51602. Consistent
with this hypothesis, cotreatment with inhibitors of glucose up-
take and metabolism, 2-deoxy-D-glucose (2-DG) and 2-fluor-
deoxy-D-glucose (2-FDG) increased the cytotoxic effect of OPB-
51602 in cancer cells (Fig. S3 A and B). Notably, OPB-51602 in
combination with 2-DG had a much greater effect in Ras-
transformed (LHS-Ras) compared with nontransformed (LHS)
prostate epithelial cells (Fig. 3A), in line with the increased de-
pendency of tumorigenic cells on mSTAT3 under glucose starvation
(6). Glucose depletion also influenced the effect of OPB-51602 on
STAT3 phosphorylation and activity. The addition of glucose
(10 mM) to CM counteracted the drug’s effect on pTyr705 and
pSer727 (Fig. 3B). Conversely, removal of glucose from FM in-
creased the efficacy of OPB-51602 (Fig. S3C). Blocking glucose
metabolism with 2-DG had a similar effect on the cell response
to OPB-51602 (Fig. S3D). Glucose starvation also enhanced the
effect of OPB-51602 on STAT3 transcriptional activity (Fig. 3C),
indicating that glucose level affected both nuclear and mito-
chondrial functions of STAT3. Together, these results indicate
that OPB-51602 exhibited higher activity toward cancer cells in
conditions of nutrient starvation or metabolic stress, which are
typically found in the tumor microenvironment in vivo (24), and
suggest the possibility of metabolic synthetic lethality because of
the drug’s impact on mitochondrial function.
To understand the basis of the striking effects in nutrient-
depleted cancer cells, we examined more closely the conse-
quences on STAT3 distribution. In addition to reduced pSTAT3,
treatment with OPB-51602 decreased the level of total STAT3
(tSTAT3). Depletion of tSTAT3, along with pSTAT3, occurred
both in the cytoplasm and nuclei (Fig. S4A). In addition, the phe-
nomenon was not affected by the state of pTyr705 phosphorylation
and its induction by IL-6 in LNCaP cells (Fig. 3D). The depletion of
tSTAT3 was highly reproducible and was particularly evident when
the cells were treated in nutrient-depleted CM. Interestingly, the
decline of tSTAT3 followed by few hours the reduction of pSTAT3,
and was more evident after 24 h of treatment (Fig. S4A).
The effect on tSTAT3 could be a consequence of reduced
transcription or enhanced protein degradation. However, STAT3
mRNA level did not change after drug treatment (Fig. S4B).
Furthermore, proteasome inhibition by PS341 did not prevent
the decline of tSTAT3 induced by OPB-51602 (Fig. S4C), ruling
out reduced transcription and enhanced degradation. We con-
sidered the alternative possibility of entrapment of STAT3 into
cellular substructures poorly solubilized under the relatively mild
conditions used for cell lysis. Indeed, lysis of cells in high-
detergent buffer increased the detectability of tSTAT3 compared
with the standard low-detergent lysis buffer, likely by disrupting the
Fig. 3. Altered distribution of STAT3 and proteostasis in response to OPB-51602. (A) Proliferation of immortalized normal (LHS) and Ras-transformed (LHS-
Ras) prostate epithelial cells treated with OPB-51602 with or without 2-DG. *P < 0.01. (B) STAT3 and pSTAT3 in H358 cells treated with OPB-51602 in CM or
glucose-supplemented CM. (C) STAT3 reporter activity in stably engineered cell lines treated with OPB-51602 for 16 h in complete or glucose-depleted FM
(GDM). *P < 0.01. (D) STAT3 and pSTAT3 in cytoplasm, nuclei, and whole-cell lysates from LNCaP treated with OPB-51602 for 16 h. (E) Distribution of STAT3,
p62, ubiquitinated proteins, and HDAC6 in cell fractions from H358 cells untreated or treated with OPB-51602 for 16 h.
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poorly soluble complexes entrapping STAT3 (Fig. S4D). To
further test this hypothesis, we performed cell fractionation and
sucrose gradient centrifugation to monitor the subcellular dis-
tribution of STAT3. In control cells total, pTyr705, and pSer727
STAT3 were mainly present in the cytoplasm, nuclei, and mi-
tochondria, respectively (Fig. S4 E and F). However, after drug
treatment most of tSTAT3 and pSTAT3 were depleted from
these cell compartments and recovered in the insoluble protein
fraction.
To confirm this finding, we used an additional cell fraction-
ation method that separated cytoplasm (fraction I), mitochon-
dria and intracellular organelles (fraction II), nuclei (fraction
III), and cytoskeleton/insoluble proteins (fraction IV) (Fig.
S4G). Using this method, we detected depletion of tSTAT3 and
pSTAT3 from cytoplasm, mitochondria, and nuclei, and a sub-
stantial shift in the insoluble protein fraction after treatment with
OPB-51602 (Fig. 3E). Intriguingly, other proteins, such as p62,
histone deacetylase 6 (HDAC6), and tubulin, which are recruited
to protein aggregates and assist in their disposal (25), relocated
in the insoluble fraction along with STAT3 in OPB-51602–treated
cells (Fig. 3E). In addition, a substantial fraction of ubiquitinated
proteins accumulated in the cellular insoluble fraction. The pres-
ence of components of the aggresome machinery and ubiquiti-
nated proteins indicated that OPB-51602 entrapped STAT3 in
aggresome-like structures and caused broad alterations in protein
homeostasis. Again, this phenomenon was enhanced by glucose
starvation and the presence of glucose-rich FM prevented the
aggregation and protein shift in the insoluble fractions (Fig. S4H).
Using confocal microscopy and EGFP-tagged STAT3, we
monitored directly the fate of STAT3 in intact cells. Control cells
exhibited a diffuse and uniform distribution of EGFP-STAT3
(Fig. 4A, Upper). In contrast, EGFP-STAT3 localized in discrete
foci resembling aggresome-like structures in cells treated with
OPB-51602 in CM (Fig. 4A, Lower). To determine whether
STAT3 aggregation was a direct consequence of the binding to the
SH2D, we examined the behavior of the E638A-STAT3 mutant
unable to bind OPB-51602 (Fig. 4B). The E638A-STAT3 mutant
did not form aggregates and retained a diffuse distribution in
drug-treated cells. Thus, the formation of the STAT3 aggregates
was a direct consequent to the interaction of the drug with the
SH2D and abrogating it prevented the aggregation.
Next, we examined whether other STAT3 domains were in-
volved in the formation of STAT3 aggregates using a series of
EGFP-STAT3 deletion mutants (Fig. 4C). The C-terminal do-
main (ΔCTD, Δ671) mutant formed aggregates in presence of
OPB-51602 (Fig. 4D). Surprisingly, the mutants lacking the
N-terminal (ΔNTD, Δ137) or both the N-terminal and coiled-coil
domain (ΔNTD-CCD, Δ312) did not aggregate in presence of
the drug, implicating these regions in the aggregation phenom-
enon. We hypothesized that the drug binding to the SH2D could
disrupt interactions between the NTD and SH2D that would
prevent self-aggregation. Based on this assumption, we generated
a mutant lacking the SH2D and CTD (ΔSH2-CTD) (Fig. 4C).
We found that the ΔSH2-CTD mutant formed spontaneous ag-
gregates that resembled the aggresome-like structures induced by
OPB-51602 (Fig. 4E). This result was in line with the hypothesis
Fig. 4. Induction of STAT3 protein aggregates by OPB-51602. (A) Distribution of EGFP-STAT3 (green) in DU145 and H358 cells untreated or treated with OPB-
51602 for 6 h in CM. Nuclei were stained with DAPI (blue). (B) Effect of OPB-51602 on WT and mutated (E638A) EGFP-STAT3. (C and D) WT and truncated
variants of EGFP-STAT3 (C) and differential responses to treatment with OPB-51602 (D). (E) Spontaneous aggregation of ΔSH2 EGFP-STAT3 variant in CM
cultures. (F) Live fluorescence, phase contrast, and composite images of H358 cells expressing WT or ΔSH2 EGFP-STAT3 at the indicated time points. Arrows
indicate the position of EGFP+ cells in phase contrast images.














that disruption of SH2D-NTD contacts could be the initial cause
of the drug-induced STAT3 aggregation.
Massive accumulation of protein aggregates can lead to pro-
teotoxicity and cell death (25, 26). Furthermore, protein aggrega-
tion is enhanced by metabolic stress and mitochondrial dysfunction
(25, 26), which also occur in OPB-51602–treated cells. To examine
whether STAT3 aggregates could per se affect cell viability, we
took advantage of the aggregation-prone ΔSH2-CTD STAT3
mutant. Cells expressing WT-STAT3 were healthy and viable (Fig.
4F). In contrast, cells expressing the ΔSH2-CTD mutant rapidly
showed signs of STAT3 aggregation and drastic changes in cell
morphology, resulting in progressive cell shrinkage and death
(Movies S1–S4). These effects were observed in cells incubated in
CM, although a detectable amount of STAT3 self-aggregates
formed also in FM. Although cells expressing WT-STAT3 di-
vided and expanded within 16–24 h, the number of cells expressing
the ΔSH2-CTD mutant did not increase because of impaired cell
division and increased cell death (Fig. S4I). Thus, the accumula-
tion of STAT3 aggregates is toxic to cells and is an important el-
ement contributing substantially to the OPB-51602 cytotoxicity.
Entrapment of p62 and Inhibition of Autophagy by Drug-Induced
Proteotoxic STAT3 Aggregates. Our data indicate that drug-
induced STAT3 aggregation is detrimental to cancer cells.
Cells have well-defined mechanisms to deal with proteotoxic
aggregates (25, 27). p62 is a critical player promoting the elim-
ination of protein aggregates through autophagy (28). However,
massive sequestration of p62 into aggresome-like structures
could result in depletion and interference with p62-dependent
processes. We found that a large portion of p62 coimmunopre-
cipitated with STAT3 in drug-treated cells, indicating that the
interaction between the two proteins increased substantially with
the formation of the STAT3 aggregates (Fig. 5A). Using confocal
microscopy, we monitored the changes in distribution EGFP-
STAT3 and Cherry-p62 in control and drug-treated cells (Fig.
5B). Individual Cherry-p62 punctae not overlapping with EGFP-
STAT3 were detected in control cells. Conversely, Cherry-p62
and EGFP-STAT3 colocalized in large aggresome-like structures
after treatment with OPB-51602. These results prompted us to
further investigate the role of p62 in the formation of the ag-
gregates. Notably, knockdown of p62 did not prevent STAT3
aggregation, indicating that p62 was not required for their for-
mation (Fig. S5A). However, deletion of the ubiquitin binding
domain (ΔUBA) in p62 reduced colocalization with EGFP-
STAT3 and caused formation of smaller and more dispersed ag-
gregates (Fig. 5C). Thus, the initial stages of aggregate formation
did not depend on p62, whereas p62 that was recruited through
the UBA domain contributed to their expansion.
Entrapment of p62 in the presence of massive formation
of STAT3 aggregates could impact on the ability of cells to ac-
tivate autophagy, an important survival mechanism in nutrient-
depleted cells (29). We found that there was no effect of OPB-
51602 on autophagy in glucose-rich FM (Fig. S5B). However,
OPB-51602 inhibited autophagy in cells treated in nutrient-
depleted CM (Fig. 5D), consistent with the notion that the
pathway was activated and susceptible to inhibition in metabol-
ically stressed cells. OPB-51602 led to the accumulation of free
cytoplasmic LC3-I and reduction of membrane-bound LC3
(LC3-II), indicating a block at the early phase of autophagosome
assembly (29) (Fig. 5E). Furthermore, treatment with the auto-
phagy inhibitor chloroquine and the proteasome inhibitor PS-
341, both alone and in combination, did not prevent the drug’s
effects on STAT3, ubiquitinated proteins, and LC3-I/II, consis-
tent with an early block of autophagy (Fig. S5C). Conversely, we
found that treatment with rapamycin, an autophagy inducer (29),
delayed the effects of OPB-51602 on LC3-I/II and partially reduced
loss of pSTAT3 at early times (≤8 h) (Fig. S5D). However, this pro-
tective effect was lost with prolonged exposure to the drug (≥16 h) and
did not block the entrapment of STAT3 in the insoluble fraction (Fig.
S5E). This finding indicated that, although autophagy initially assist in
the disposal of STAT3 aggregates, prolonged exposure to OPB-
51602 exhausts the cell capacity for processing them, leading to the
accumulation of proteotoxic aggregates. In this context, the mito-
chondrial dysfunction induced by OPB-51602 could further exac-
erbate the formation of aggregates and prevent their elimination.
Mitochondrial Dysfunction and Proteotoxic Aggregate Formation
Occur with Other STAT3i. Treatment with OPB-51602 induced a
complex cascade of events contributing to the drug’s cytotoxicity.
These events depend primarily on the binding of OPB-51602 to
the SH2D, leading to impaired STAT3 function and aggregation.
We examined whether other STAT3i induced similar effects. We
selected compounds reported to interact with the STAT3 SH2D
(11), although they differ in their mode of interaction and
binding affinity, as we recently reported for some of them (22).
We also included WP1066, which was initially described as a
JAK2 inhibitor (30) and later shown to block also SH2D–protein
interactions independently of pTyr705 phosphorylation and nu-
clear STAT3 activity (31), suggesting an alternative mechanism
of interference with STAT3 functions. Notably, we found that all
of these compounds impaired MMP and ATP production (Fig.
S6A), indicating that mitochondrial dysfunction was a common
event. Sensitivity to these compounds was also affected by glucose
starvation (Fig. S6B) and their cytotoxic activity was enhanced by 2-
DG (Fig. S6C). STA21 and WP1066 progressively reduced pTyr705,
pSer727, and tSTAT3 in cells treated in glucose-free medium, as
seen with OPB-51602 (Fig. S6D). The STAT3i also induced the
inclusion of STAT3 in insoluble complexes (Fig. S6 E–H) and for-
mation of STAT3 aggregates (Fig. 5B), in line with an interference
with SH2D functions. Similar to OPB-51602, many of these com-
pounds inhibited autophagy in nutrient-starved cells (Fig. S7A).
Conversely, the JAK2 inhibitor NVP-BSK805 (32) did not affect
mitochondria (Fig. S6A), autophagy (Fig. S7A), and STAT3 in-
tracellular distribution (Fig. S7B). Thus, the effects on mitochon-
drial activity, STAT3 aggregation, and protein homeostasis were
phenomena shared by most, if not all of the compounds interfering
with STAT3 function directly. Furthermore, the induction of pro-
teotoxic cell death in metabolically stressed cancer cells was a
common event underlying the anticancer activity of these STAT3i.
Proteotoxic STAT3 Aggregate Formation and in Vivo Antitumor
Activity of OPB-51602. Tumor cells in the in vivo tumor microen-
vironment experience metabolic stress because of nutrient and
glucose starvation (24). Our present data suggest that in this
condition, tumor cells might be highly sensitive to STAT3i. A key
event induced by OPB-51602 was the depletion of STAT3 and
the formation of protein aggregates, which were direct conse-
quences of the binding to STAT3 and were enhanced by nutrient
depletion. We examined whether OPB-51602 induced similar
effects in vivo. Mice with DU145 tumor xenografts were treated
with vehicle or OPB-51602 daily for 3 or 5 d. The level of
pTyr705, pSer727, and tSTAT3 declined in tumors from OPB-
51602–treated mice (Fig. 6 A and B). Ki67 immunostaining was
also reduced, confirming the concomitant inhibition of tumor cell
proliferation. Moreover, aggresome-like structures, similar to those
detected in vitro, were observed in tumor xenografts from OPB-
51602–treated mice using ProteoStat, a specific stain for protein
aggregates (Fig. 6C,Upper). Aggresome formation peaked at day 5,
along with the reduction of tSTAT3. Immunofluorescence mi-
croscopy showed the concomitant formation of p62+ aggregates in
OPB-51602–treated mice with a similar kinetics (Fig. 6C, Lower).
These results confirmed the induction of STAT3 and p62-rich
aggregates in tumor xenografts, suggesting that this phenomenon
could be relevant for the drug’s activity in vivo.
Next, we assessed the impact of OPB-51602 on the growth of
DU145 tumor xenografts. Treatment with OPB-51602 daily for
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2 wk strongly suppressed tumor growth as assessed by tumor
volume (Fig. 6D), in vivo bioluminescence (Fig. S8A), and tu-
mor weight (Fig. S8B) measurements. Immunohistochemistry
(IHC) showed marked reduction of pTyr705, pSer727, and Ki67,
confirming the ability of OPB-51602 to inhibit STAT3 signaling
and tumor cell proliferation in vivo (Fig. 6 E and F). Notably,
Fig. 5. Entrapment of p62 in STAT3-rich aggresomes. (A) Coimmunoprecipitation of STAT3 and p62 upon lysis in DISK buffer of control and OPB-51602–
treated H358 cells. (B) Distribution of EGFP-STAT3 (green) and Cherry-p62 (red) in cells treated with the indicated drugs for 6 h in CM cultures. (C) Distribution
of EGFP-STAT3 (green) and WT or ΔUBA Cherry-p62 (red) in cells treated with OPB-51602 for 6 h in CM. (D) Flow cytometry analysis of autophagy in H358 and
DU145 cells treated with OPB-51602 for 6 h in CM. (E) Immunoblot analysis of LC-3 along with STAT3, p62, and ubiquitinated proteins in H358 cells treated
with OPB-51602 for the indicated time in CM cultures.














tumor growth did not resume in the 2-wk following treatment
discontinuation, suggesting that OPB-51602 impaired the repo-
pulating capacity of the surviving cancer cells in the residual
tumors. We reasoned that this inhibition of tumor regrowth
could be because of depletion of stem-like cancer cells, which
would determine tumor cell repopulation. Prostate cancer stem-
like cells are highly depended on STAT3 and sensitive to its
inhibition (33–35). To test our hypothesis, we assessed the
fraction of stem-like cancer cells in tumor xenografts after OPB-
51602 treatment using ex vivo flow cytometry and tumor-sphere–
forming assays (36, 37). These assays reliably monitor the stem-
like cancer cell subpopulation in tumor xenografts, showing high
correlation with the tumorigenic capability of stem-like cancer
cells in vivo (36, 37). Notably, the fraction of CD44+/CD24− (Fig.
S8C) and ex vivo tumor-sphere–forming cells (Fig. S8D), repre-
senting the surviving stem-like cancer cells in tumor xenografts,
decreased significantly in the OPB-51602–treated group. Thus,
OPB-51602 induced a substantial depletion of tumor-initiating
stem-like cancer cells in line with the prolonged impairment of
the tumor cell repopulating capability in vivo.
Discussion
STAT3 has a pivotal role in multiple oncogenic processes and is
emerging as an important cancer therapeutic target (2, 12). In
this study we examined the mechanism by which a small-
molecule inhibitor that binds to the SH2D interferes with
STAT3 functions in cancer cells. We found that the high-affinity
STAT3i, OPB-51602, triggers a complex cascade of events
leading to interference with multiple cellular functions and cul-
minating in cell death. We dissected the contribution of each
element of this cascade to the cytotoxic activity of this com-
pound. Our data show that interference with mSTAT3, mito-
chondrial dysfunction, and formation of STAT3 proteotoxic
aggregates were central events for the lethal effects in cancer
cells exposed to nutrient starvation and metabolic stress. These
findings challenge the current view that inhibition of nuclear
STAT3 signaling and transcriptional activity are the main ele-
ments underlying the in vivo antitumor activity of STAT3i (2,
12). Moreover, these data open new perspectives for the clinical
use of this class of anticancer drugs.
Our findings are consistent with a central role of mSTAT3 in
sustaining survival of cancer cells in conditions of metabolic
stress (5–7). Binding of OPB-51602 to the SH2D was the initial
trigger for the disruption of intradomain interactions and the
formation of STAT3 aggregates. This initial event, then, had
broad consequences on many cellular processes starting with
impairment of mSTAT3 functions. This was also associated with
impaired STAT3 nuclear and transcriptional activity, although
this occurred at later times and was not sufficient for the in-
duction of cytotoxic effects in mitochondrial-depleted DU145 ρ°
Fig. 6. Inhibition of tumor growth and impairment of tumor-initiating stem-like cells in vivo. (A and B) STAT3, pSTAT3, and Ki67 in DU145 tumor xenografts
after treatment with OPB-51602 (40 mg/kg, daily bymouth) for 3 and 5 d and off treatment for 2 d (5+2). Representative images (A) and IHC quantification (B). (C)
Aggresome formation in DU145 tumor xenografts from control and OPB-51602–treated mice (40 mg/kg, daily by mouth) detected by ProteoStat staining (Upper)
or p62 immunostaining (Lower). Arrows, large aggregates in drug-treated xenografts. (D) Growth of tumor xenografts of DU145 cells in mice treated with
20 mg·kg·d–1 of OPB-51602 (n = 5 per group). (E and F), pTyr705 STAT3, pSer727 STAT3, and Ki67 IHC in tumor xenografts of DU145 cells in mice treated with
vehicle or 20 mg·kg·d–1 OPB-51602 for 2 wk. Quantification of pTyr705, pSer727 STAT3 and Ki67 immuno-staining (E) and representative images (F). *P < 0.01.
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cells. Conversely, we observed rapid changes in mitochondrial
activity after treatment with OPB-51602. Consistent with im-
paired mitochondrial function, the drug induced profound ef-
fects on mitochondria morphology, indicating an imbalance
between fusion and fission events and accumulation of frag-
mented mitochondria (38, 39). Changes in mitochondrial dy-
namics and energy homeostasis are emerging as important
elements in cancer (18, 19). These processes might be particu-
larly relevant for tumor-initiating cancer stem-like cells, which
exhibit greater metabolic plasticity (40, 41) and often increased
reliance on mitochondrial functions (42–44). We show that the
drug’s lethal effects were directly related to the interference with
mSTAT3 and mitochondrial function using isolated mitochondria
from STAT3−/− MEF and mitochondria-depleted cancer cells,
which were insensitive to OPB-51602. Conversely, we found that
conditions that increased the cell dependency on mitochondria,
like glucose starvation, increased the response to STAT3i. This
phenomenon was particularly evident in Ras-transformed cells
compared with nontransformed prostate epithelial cells, indicating
a potential selectivity of this approach toward cancer cells. Nota-
bly, limited nutrient and glucose availability are commonly faced
by cancer cells in the tumor microenvironment in vivo (24, 45, 46).
Our study shows that the cell lethality induced by OPB-
51602 derived from a combination of events, among which mi-
tochondrial dysfunction and altered proteostasis had major roles.
Mitochondria have an important function in preventing protein
misfolding and aggregation (25). Mitochondrial dysfunction,
particularly in glucose-depleted conditions, could contribute to
the drug-induced accumulation of STAT3 aggregates. Further-
more, despite the ability of the autophagy and proteasomal
machinery to remove protein aggregates (25–27), the progressive
accumulation of aggresomes caused the sequestration of essen-
tial components of the autophagy and proteasomal system and
saturated the capacity of the cells to dispose of protein aggre-
gates. Impaired autophagy and proteostasis compromised the
survival of cancer cells under nutrient starvation. This combi-
nation of events can lead to a total collapse of cell functions and
proteotoxic cell death (25–27, 47). Mitochondrial dysfunction,
impaired proteostasis, and proteotoxic cell death are commonly
seen in many neurodegenerative diseases (25–27, 47, 48). Our
data indicate that cancer cells under specific growth conditions
are highly susceptible to the metabolic imbalance and proteo-
toxic stress induced by STAT3i.
Importantly, the relevance of mSTAT3 and its mitochondrial
functions, which emerges from this study, raises the possibility
that features linked to the tumor metabolic status, such as the
degree of mitochondrial or glucose dependency, could identify
tumors more likely to respond to STAT3i (24, 42, 49, 50). Fur-
thermore, metabolic reprogramming with increased reliance on
mitochondrial function has emerged as an important mechanism
for survival of tumor-initiating cells and development of therapy-
induced resistance (42, 50–52). Our data suggest the interesting
hypothesis that these phenomena might be specifically associated
with enhanced vulnerability of cancer cells to STAT3i. Thus,
OPB-51602 and other STAT3i could take advantage of the
Achilles’ heel represented by the specific metabolic dependencies
of cancer cells and tumor-initiating cells and elicit a metabolic
synthetic lethality effect (53, 54).
The strategies used by cancer cells to ensure survival in the in
vivo tumor microenvironment may vary depending on the tumor
type, primary and metastatic sites, and epigenetically distinct
cancer cell subpopulations (49, 55). Metabolic adaptation is
emerging as a major mechanism of cancer cell survival and
treatment resistance (20, 54). Decoding the processes involved
in metabolic reprogramming in cancer cells, and particularly
tumor-initiating stem-like cancer cells, is key to identifying novel
targets and envisioning new therapeutic strategies (19, 56, 57).
Our data indicate that STAT3 is an important factor in this
context because of its involvement in key metabolic and survival
pathways through both its nuclear and nonnuclear functions.
Moreover, drugs like OPB-51602 block STAT3 in multiple cell
compartments and interfere effectively with the metabolic flex-
ibility essential for survival of cancer cells in the challenging
tumor microenvironment.
Methods
Detailed description of reagents and protocols is provided in SI Materials
and Methods.
Cell Lines and Reagents. All of the cell lines, including LHS and LHS-Ras cells,
have been described previously (52). DU145 ρ° cells were produced by con-
tinuous culturing in the presence of ethidium bromide (50 ng/mL) and were
maintained in RPMI supplemented with uridine (10 mg/mL) and sodium
pyruvate (1 mM). OPB-51602 and OPB-31121 were obtained from Otsuka
Pharmaceuticals. Sources of all other chemicals and antibodies are indicated
in SI Materials and Methods. Treatments were performed in complete RPMI,
glucose-free RPMI, or conditioned medium. Cell fractionation was per-
formed using ProteoExtract Subcellular Proteome Extraction Kit (Merck) or
sucrose gradient centrifugation. Tumor-sphere formation and assessment of
stem-like subpopulation (CD44+/CD24− cells) by flow cytometry were per-
formed as described previously (37). Mitochondria were isolated with Mi-
tochondria Isolation Kit (Thermo Scientifics). Mitochondria membrane
potential was assesses with JC-1 or DIOC6 (ENZO). OCR was measured on a
Seahorse XFp Analyzer (Seahorse Bioscience). All assays were performed in
triplicate and repeated in at least three independent experiments.
Animal Studies. All protocols were approved by the Swiss Veterinary Au-
thority. DU145-Luc cells were injected subcutaneously in athymic male nude
mice. Mice were treated with OPB-51602 in 5% arabic gum or vehicle. Tumor
growth was monitored with a caliper and in vivo bioluminescence imaging
using an IVIS Spectrum (Caliper LifeSciences). Ex vivo assays to assess stem-like
cancer cells in tumor tissues were performed as previously described (36, 37).
Statistical Analysis. Differences between experimental groups were analyzed
for statistical significance using unpaired two-tailed t test. P values ≤ 0.01
were considered statistically significant.
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